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The human gut microbiome is involved in vital biological
functions such as maintenance of immune homeostasis,
modulation of intestinal development and enhanced meta-
bolic capabilities. Disturbances of intestinal microbiota have
been associated with development and progression of in-
ﬂammatory conditions including GVHD. Non-secretor in-
dividuals do not express the H antigen on mucosal surfaces
and body ﬂuids due to a homozygous single nucleotide
polymorphism in the fucosyltransferase 2 (FUT2) gene
(428G>A) and FUT2 genotype has been shown to modify the
gut microbiome. We hypothesized that FUT2 genotype in-
ﬂuences risk of GVHD and bacterial translocation following
allogeneic HSCT.
FUT2 genotype was determined in 150 consecutive patients
receiving allogeneic HSCT at our center. We abstracted clin-
ical characteristics and outcomes from the transplant
database.
Median age at transplantationwas 6.31 years andmale/female
ratio was 97/53. Genetic analysis revealed 23% recipients had
A/A genotype (n¼34), 52% A/G genotype (n¼78) and 25% G/G
genotype (n¼38); Hardy Weinberg equilibrium was con-
ﬁrmed. Hematologicmalignancies comprised 30% (n¼45), 29%
immune deﬁciencies (n¼43), 22% bonemarrow failure (n¼33),
12% hemophagocytic lymphohistiocytosis (HLH) (n¼18), 4%
metabolic diseases (n¼6), 3% hemoglobinopathies (n¼4), and
one patient with Evan’s syndrome. 54% receivedmyeloablative
conditioning (n¼81), while 46% received reduced intensity
conditioning (n¼68). Stem cell source was bone marrow in
81% (n¼122), peripheral blood stem cells in 11% (n¼16), cord
blood in 7% (n¼11), and one patient received both bone
marrow and cord blood from a sibling donor. Among donors,29% were matched sibling donors (n¼43), 49% matched un-
related or other family member donors (n¼74) and 22% were
mismatched donors (n¼33). Acute GVHD occurred in 36% of
patients (n¼54). Cumulative risk of any acute GVHD varied by
FUT2 genotypewith decreased risk in thosewith A/A genotype
and increased risk in those with G/G genotype (p¼0.04) (Fig.
1). A/A genotype (OR¼0.4 p-value¼0.046), myeloablation
(OR¼1.99 p-value¼0.029) and matched sibling donor
(OR¼0.41 p-value¼0.026) were identiﬁed to be signiﬁcant
GVHD risk factors in multivariate analysis. Bacteremia
occurred in 34% of patients (n¼51), and in contrast to our
ﬁndings in GVHD cumulative incidence was increased in A/A
genotype (p-value¼0.01) (Fig. 1). A/A genotype (OR¼3.94 p-
value¼0.0047) and A/G genotype (OR¼2.46 p-value¼0.05)
were associated with increased risk in multivariate analysis.
FUT2 genotype inﬂuences risk of acute GVHD and bacteremia
following HSCT. We hypothesize that the mechanism in-
volves altered composition and diversity of gut microbiome,
and limited data indicate increased diversity of the gut
microbiome in the A/A genotype, but this requires additional
studies.105
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Introduction: AutoHCT is a potentially curative modality for
Rel/Ref HL. However, large studies evaluating the risk factors
predicting outcomes of autoHCT in CAYA with Rel/Ref HL
have not been performed.
